Stay updated on Aptose Biosciences Press Releases

Sign up to get notified when there's something new on the Aptose Biosciences Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the Aptose Biosciences Press Releases page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    A new press release entry announces the completion of Aptose's acquisition by Hanmi Pharmaceutical (Jun 30, 2026). The old release about Tuspetinib's ASH 2025 data has been removed from the list.
    Difference
    2%
    Check dated 2026-07-06T15:51:19.000Z thumbnail image
  3. Check
    17 days ago
    No Change Detected
  4. Check
    24 days ago
    Change Detected
    Summary
    A new press release entry appears for Tuspetinib data at the 2026 EHA Congress, and an older acquisition-related release by Hanmi Pharmaceutical is deleted from the list.
    Difference
    2%
    Check dated 2026-06-22T09:17:58.000Z thumbnail image
  5. Check
    46 days ago
    Change Detected
    Summary
    A new press release entry dated May 29, 2026, titled 'Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical' was added to the press releases list, and the Nov 13, 2025 'Aptose Reports Third Quarter 2025 Results' release was removed.
    Difference
    2%
    Check dated 2026-06-01T01:16:49.000Z thumbnail image
  6. Check
    60 days ago
    Change Detected
    Summary
    Added a new press release entry for Aptose Reports First Quarter 2026 Results dated May 13, 2026, and removed the older Aptose Tuspetinib Clinical Data from Ongoing TUSCANY Trial in Newly Diagnosed AML Selected for Presentation at the 2025 ASH Annual Meeting from the press releases listing.
    Difference
    2%
    Check dated 2026-05-17T09:59:11.000Z thumbnail image
  7. Check
    75 days ago
    Change Detected
    Summary
    Added a new press release entry dated Apr 30, 2026 announcing the anticipated timing of the closing of the Plan of Arrangement with Hanmi Pharmaceutical; removed an older release about Aptose’s Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML.
    Difference
    2%
    Check dated 2026-05-03T00:58:36.000Z thumbnail image
  8. Check
    104 days ago
    Change Detected
    Summary
    Added a new press release dated Mar 31, 2026: Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 2025 Results and Corporate Highlights. Deleted the Sep 22, 2025 press release: Aptose and Hanmi Pharmaceutical Extend Loan Agreement to Continue Development of Tuspetinib in Triplet Therapy for AML.
    Difference
    2%
    Check dated 2026-04-04T05:23:20.000Z thumbnail image

Stay in the know with updates to Aptose Biosciences Press Releases

Enter your email address, and we'll notify you when there's something new on the Aptose Biosciences Press Releases page.